Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomised, 2-arm, Parallel-group, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Subcutaneous Methotrexate Versus Placebo in Moderate to Severe Atopic Dermatitis.

NCT06239311 is registered in ClinicalTrials.gov with medac GmbH as lead sponsor.

NCT NCT06239311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06239311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomised, 2-arm, Parallel-group, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Subcutaneous Methotrexate Versus Placebo in Moderate to Severe Atopic Dermatitis.
Lead sponsor
medac GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
February 27, 2024
Completion date
April 30, 2027
Enrollment
277 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe atopic dermatitis